PATENT CLAIM ANALYSIS

Application Number: 16264434
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-06
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

Claim (Index 1):
A method of cancer immunotherapy comprising administering to a subject in need thereof chimeric antigen receptor-modified immune cells (CAR-MIC) and an immunomodulatory retinoid active agent and/or rexinoid active agent (RAR/RXR active agent), and a differentiating RAR active agent, wherein the immunomodulatory RAR/RXR active agent is:\n a) a RAR\u03b1 antagonist, wherein the RAR\u03b1 antagonist is:\n i) a compound of general formula (I) \n wherein R1, R2, R3, and R6 are independently H or C1-6 alkyl; R4 and R5 are independently H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is C(CH3)2, O, S, or NR7, wherein R7 is H or C1-6 alkyl; X1 is H or halogen such as F, Cl or Br; and R8 is H or OH; or ii) a compound of general formula (II) wherein R1 and R2 are independently C1-6 alkyl; X is O, S, or CH2; Y is O, S, CH2, or NR3, wherein R3 is C1-6 alkyl; Z is Cl or Br; W is H or OH; and U is independently H or F; or iii) a compound of general formula (III): wherein R1 and R2 are independently H or C1-6 alkyl; R3 is H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is O, S, N, or CH2; W is H or OH; and Z is Cl or Br; or iv) BMS185411, BMS614, Ro41-5253, Ro46-5471, or AGN 194777; or b) a RAR  agonist, wherein the RAR  agonist is:\n i) a compound of general formula (IV): \n wherein R1 and R2 are independently H or C1-6 alkyl; R3 is H or F; and X is O, S, CH2, C(R4)2, or NRS, wherein R4 and R5 are independently H or C1-6 alkyl; or or\n iii) CD437, CD2325, CD666, or BMS961; or \n c) a RXR antagonist, wherein the RXR antagonist is:\n AGN195393, LGN100849, \n \n or\n d) a combination thereof; and \n wherein the differentiating RAR active agent is a RAR\u03b1 agonist, wherein the RAR\u03b1 agonist is a compound of general formula (V): wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 99.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16034123', '16117372', '16034064', '15868469', '15620411']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7703178512691954
- 35 USC 102 Novelty (BERT): 0.7337150314329456
- Combined Prediction Score: 0.7666575692855704
- Mean Citation Score: 608.9010599999998
- Max Citation Score: 917.8652
- Similarity Product: 790.4589769315004

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test